共 16 条
- [2] IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma .[J].Xu Junnv;Lin Haifeng;Wu Gang;Zhu Mingyue;Li Mengsen.Frontiers in Oncology.2021,
- [3] BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update..[J].Reig M;Forner A;Rimola J;FerrerFábrega J;Burrel M;GarciaCriado A;Kelley R K;Galle P R;Mazzaferro V;Salem R;Sangro B;Singal A G;Vogel A;Fuster J;Ayuso C;Bruix J.Journal of hepatology.2021, 3
- [6] VEGF in Signaling and Disease: Beyond Discovery and Development [J]. CELL, 2019, 176 (06) : 1248 - 1264
- [7] Current topics in the surgical treatments for hepatocellular carcinoma [J]. ANNALS OF GASTROENTEROLOGICAL SURGERY, 2018, 2 (02): : 137 - 146
- [8] TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway..[J].Brian Tomkowicz;Eileen Walsh;Adam Cotty;Raluca Verona;Nina Sabins;Fred Kaplan;Sandy Santulli-Marotto;Chen-Ni Chin;Jill Mooney;Russell B Lingham;Michael Naso;Timothy McCabe.PLoS ONE.2017, 10
- [10] IL-6; through p-STAT3 rather than p-STAT1; activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study..[J].Kao Jung-Ta;Feng Chun-Lung;Yu Cheng-Ju;Tsai Shu-Mei;Hsu Ping-Ning;Chen Yao-Li;Wu Yi-Ying.BMC gastroenterology.2015, 1